December 9, 2024 01:30 PM EST
R&D
Pharma

GSK re­ports Blenrep over­all sur­vival da­ta in mul­ti­ple myelo­ma as it plots mar­ket reen­try

Nicole DeFeudis

Editor

SAN DIEGO — Two years af­ter pulling Blenrep from the mar­ket, GSK is po­si­tion­ing for a re­launch.

This time, the com­pa­ny says it’s com­ing from a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

J&J’s Spra­va­to hit $1B in rev­enue in 2024

Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times